Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).
Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.
Capolongo
L
L
Farmitalia Carlo Erba, Research Center, Oncology Department, Nerviano, Milano, Italy.
Melegaro
G
G
Broggini
M
M
Mongelli
N
N
Grandi
M
M
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002352:Carrier Proteins / Q000235:genetics; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D004214:Distamycins / Q000494:pharmacology*; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002352:Carrier Proteins; D004214:Distamycins; D008562:Membrane Glycoproteins; D009588:Nitrogen Mustard Compounds; C066900:tallimustine; D014700:Verapamil